Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FMP012 + GLA-SE
- Development stage
- Unknown
- Lead developer
- Walter Reed Army Institute of Research
- Modality
- Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
FMP012 + GLA-SE is an investigational malaria vaccine candidate composed of the recombinant protein antigen FMP012 (a form of Plasmodium falciparum Cell-Traversal protein for Ookinetes and Sporozoites, or CelTOS) formulated with the adjuvant GLA-SE (Glucopyranosyl Lipid A-Stable Emulsion). The vaccine is designed to induce both humoral and cellular immune responses against P. falciparum sporozoites. FMP012 is produced in E. coli and targets the pre-erythrocytic stage of malaria infection by aiming to block parasite traversal in host tissues. The adjuvant GLA-SE acts as a Toll-like receptor 4 agonist to enhance immunogenicity by promoting a Th1-type immune response. This combination has been evaluated in phase 1 clinical trials for safety, immunogenicity, and protective efficacy against controlled human malaria infection[2][9][1].
- Other names
- PfCelTOS FMP012/GLA-SE
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on FMP012 + GLA-SE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FMP012 + GLA-SE.